# US 2010/0168430 A1 · Multikinase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168430 A1
- Document ID: US20100168430A1
- Status: Published application
- Kind: A1
- Application number: 11/997,967
- Filed: 2006-08-04
- Published: 2010-07-01
- Earliest claimed: 2005-08-05
- Assignees: Chugai Seiyaku Kabushiki Kaisha; The University of Tokyo
- Inventors: Sawako Ozawa; Nobuhiro Oikawa; Eisaku Mizuguchi; Hirosato Ebiike; Fumio Watanabe; Kenji Morikami; Nobuo Shimma; Nobuya Ishii; Toshiyuki Tsukaguchi; Yasuhiro Tamaki; Hidenori Takahashi
- Web page: https://patentgrep.com/patent/US20100168430A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

It is intended to provide a compound represented by the formula (1): [wherein Ar is an arylene group to be attached selected from the following formula (2): (wherein * represents a binding site to a nitrogen atom and ** represents a binding site to T); T represents —(O)n—R; R represents a C1-C6 alkyl group or the like; n represents 0 or 1; X represents O or the like; R2, R3 and R4 are independently selected from a hydrogen atom or C1-C3 alkyl; or R2 and R3 may join together with an urea structure containing the nitrogen atoms to which they bind to form a 5- or 6-membered heterocycle; Y represents CH or N], or a pharmaceutically acceptable salt thereof or a prodrug thereof and a pharmaceutical composition containing the same.

## Claims

### Claim 1

A compound represented by Formula (1) of:
a pharmaceutically acceptable salt thereof, or a prodrug thereof,
wherein
Ar is an arylene linking group selected from the following formulae:
wherein * represents a binding site to the nitrogen atom, and ** represents a binding site to T;
T is —(O)n-R;
R is selected from the group consisting of a C1-C6 alkyl group, a C3-C8 cycloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a phenyl group, a tetrahydrofuranyl group, a tetrahydrothiopyranyl group, a 1-oxotetrahydrothiopyranyl group, a 1,1-dioxotetrahydrothiopyranyl group, and a tetrahydropyranyl group, wherein each of these groups may be optionally substituted by one to three substituents independently selected from the group consisting of a hydroxyl group, an oxo group, a halogen atom, and a C1-C6 alkoxy group;
n is 0 or 1;
X is O, S(O)m, CH2, C═O, or NR1, wherein m is an integer of 0 to 2, and R1 is H or a C1-C3 alkyl group;
R2, R3 and R4 are independently selected from the group consisting of a hydrogen atom and C1-C3 alkyl, where the alkyl group may be optionally substituted by one to three substituents independently selected from the group consisting of a hydroxyl group, an oxo group, a C1-C3 alkoxy group, and a C1-C3 alkoxy-C1-C3 alkoxy group; or
R2 and R3 together with the urea structure containing the nitrogen atoms to which they are bonded may form a 5- or 6-membered heterocycle, which may be optionally substituted by one to three substituents independently selected from the group consisting of an oxo group and a hydroxyl group; and
Y is CH or N.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein X is O, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R is a C1-C6 alkyl group or a tetrahydropyranyl group, wherein each of these groups may be optionally substituted by one to three substituents independently selected from the group consisting of halogen atoms and a C1-C6 alkoxyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein Y is CH, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein Y is N, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein the compound is selected from the followings:
1-[4-(2-methoxyethoxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(2-methoxyethoxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[5-(2-methoxyethoxy)naphthalen-2-yl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[4-(tetrahydropyran-4-yloxy)-3-(trifluoromethyl)phenyl]urea;
1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[3-(tetrahydropyran-4-yloxy)-5-(trifluoromethyl)phenyl]urea;
1-[4-(3-fluoropropyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(3,3-difluoropropyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)phenyl]urea;
1-[4-(2-fluoroethoxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(3-fluoropropyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[4-trifluoromethoxy-3-(trifluoromethyl)phenyl]urea;
1-[4-(2-fluoroethyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[3-(2-fluoroethyl)-5-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(2-fluoroethyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[3-(2-fluoroethyl)-5-(trifluoromethyl)phenyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[3-(3-fluoropropyl)-5-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[3-(3,3-difluoropropyl)-5-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorobutyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorobutyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[3-(4-fluorobutyl)-5-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[3-(4,4-difluorobutyl)-5-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[5-(2-fluoroethyl)naphthalen-2-yl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[5-(2,2-difluoroethyl)naphthalen-2-yl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[5-(3-fluoropropyl)naphthalen-2-yl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-(3,5-bis(trifluoromethyl)phenyl)-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-(4-fluoromethyl-3-trifluoromethylphenyl)-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(3-fluoro-3-methylbutyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[3-trifluoromethyl-4-(3,3,3-trifluoropropyl)phenyl]urea;
1-(4-ethyl-3-trifluoromethylphenyl)-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-(3-trifluoromethyl-4-vinylphenyl)urea;
1-[4-(2-isopropoxy-ethoxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[3-(2-isopropoxy-ethoxy)-5-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]-3-[4-(tetrahydropyran-4-yloxy)-3-(trifluoromethyl)phenyl]urea;
1-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]-3-[3-(tetrahydropyran-4-yloxy)-5-trifluoromethylphenyl]urea;
1-[4-(2,2-difluoroethoxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[3-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]urea;
1-[3-(2,2-difluoroethoxy)-5-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(2,2-difluoroethyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(2,2-difluoroethyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[3-(2,2-difluoroethyl)-5-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[3-(2,2-difluoroethyl)-5-(trifluoromethyl)phenyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(3,3-difluoropropyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4,4-difluorobutyl)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(2-fluoro-1-fluoromethyl-ethoxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(2-fluorophenoxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorophenoxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(3-fluorophenoxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(2-fluoro-1-fluoromethyl-ethoxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(3-fluorocyclohexyloxy)-3-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[3-(2-fluoro-1-fluoromethyl-ethoxy)-5-(trifluoromethyl)phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(2-fluoroethyl)-3-trifluoromethyl-phenyl]-3-[4-(1-methyl-1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(2,2-difluoroethoxy)-3-trifluoromethyl-phenyl]-3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-3-[4-(1-methyl-1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-3-[4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
3-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-1-methyl-1-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-1-methyl-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
3-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-1-methyl-1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-1-methyl-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(2-fluoroethyl)-3-trifluoromethyl-phenyl]-1-methyl-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(2,2-difluoropropyl)-3-trifluoromethyl-phenyl]-1-methyl-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-1,3-dimethyl-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluoro-phenoxy)-3-trifluoromethyl-phenyl]-3-[4-(1-methoxymethyl-1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-3-[4-(1-methoxymethyl-1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-3-{4-[1-(2-methoxy-ethoxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yloxy]phenyl}urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-3-{4-[1-(2-methoxy-ethoxymethyl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy]phenyl}urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-1,3-bis(methoxymethyl)-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
3-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-1-methoxymethyl]-1-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-1-methoxymethyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]urea;
3-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-1-methoxymethyl]-1-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-1-methoxymethyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]urea;
1-[4-(1-acetyl-1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]-3-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]urea;
1-[4-(1-acetyl-1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]urea;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-4,5-dihydroxy-3-[4-(1H-pyrazolo[3,4-b] pyridin-4-yloxy)phenyl]imidazolidin-2-one;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-4,5-dihydroxy-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]imidazolidin-2-one;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-4,5-dihydroxy-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]-1,3-dihydroimidazol-2-one;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-4,5-dihydroxy-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,3-dihydroimidazol-2-one;
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-3-[4-(1H-pyrazolo[3,4-b]pyridin-4-yloxy)phenyl]imidazolidine-2,4,5-trione; and
1-[4-(4-fluorophenoxy)-3-trifluoromethyl-phenyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]imidazolidine-2,4,5-trione,
or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

### Claim 7 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, which is used for prevention or treatment of a disease selected from the group consisting of cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis, endometriosis, and diabetic retinopathy.

### Claim 8 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, which is used for prevention or treatment of age-related macular degeneration.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising, as an active ingredient, the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

### Claim 10 (depends on 1)

A kinase inhibitor having a cell proliferation inhibitory effect and/or an angiogenesis inhibitory effect, comprising the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

### Claim 11 (depends on 1)

A drug used for prevention or treatment of a disease selected from the group consisting of cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis, endometriosis, and diabetic retinopathy, comprising, as an active ingredient, the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

### Claim 12 (depends on 1)

A drug used for prevention or treatment of age-related macular degeneration, comprising, as an active ingredient, the compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
